We are live on ! Find out more
BI

BVF Inc Portfolio holdings

AUM $3.14B
1-Year Est. Return 249.53%
This Fund
S&P 500
This Quarter Est. Return
-26.78%
1 Year Est. Return
+249.53%
3 Year Est. Return
+690.11%
5 Year Est. Return
+1,011.36%
10 Year Est. Return
+22,702.25%
AUM
$765M
AUM Growth
-$373M
Cap. Flow
-$25.7M
Cap. Flow %
-3.36%
Top 10 Hldgs %
52.72%
Holding
58
New
1
Increased
22
Reduced
25
Closed
3

Top Buys

Rank Stock Value
1
RCUS icon
Arcus Biosciences
RCUS
+$15.8M
2
KURA icon
Kura Oncology
KURA
+$10.1M
3
MRUS
Merus
MRUS
+$8.69M
4
VSTM icon
Verastem
VSTM
+$7.77M
5
EIGR
Eiger BioPharmaceuticals, Inc.
EIGR
+$7.27M

Top Sells

Rank Stock Value
1
IONS icon
Ionis Pharmaceuticals
IONS
+$26M
2
ARRY
Array Biopharma Inc
ARRY
+$23.5M
3
XNCR icon
Xencor
XNCR
+$8.96M
4
PTGX icon
Protagonist Therapeutics
PTGX
+$7.76M
5
CYTK icon
Cytokinetics
CYTK
+$7.6M

Sector Composition

Rank Sector Weight
1 Healthcare 83.41%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
CCXI
1
DELISTED
ChemoCentryx, Inc.
CCXI
$73M 9.54%
6,687,523
-86,237
-1% -$909K
ARRY
2
DELISTED
Array Biopharma Inc
ARRY
$67.6M 8.83%
4,744,062
-1,546,524
-25% -$23.5M
MRUS
3
DELISTED
Merus
MRUS
$63.2M 8.26%
4,514,913
+600,000
+15% +$8.69M
KURA icon
4
Kura Oncology
KURA
$826M
$39M 5.09%
2,775,156
+759,300
+38% +$10.1M
BPMC
5
DELISTED
Blueprint Medicines
BPMC
$31M 4.05%
574,967
-23,300
-4% -$1.42M
MRTX
6
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
$29.2M 3.82%
688,851
-34,471
-5% -$1.37M
CYTK icon
7
Cytokinetics
CYTK
$10.9B
$26.2M 3.43%
4,150,639
-1,036,200
-20% -$7.6M
RCUS icon
8
Arcus Biosciences
RCUS
$3.55B
$26M 3.39%
2,411,623
+1,352,783
+128% +$15.8M
FPRX
9
DELISTED
Five Prime Therapeutics, Inc.
FPRX
$25.9M 3.38%
2,781,346
-599,771
-18% -$7.14M
XOMA
10
DELISTED
Xoma
XOMA
$22.4M 2.92%
1,769,029
+266,229
+18% +$3.81M
XNCR icon
11
Xencor
XNCR
$1.59B
$21.5M 2.8%
593,465
-244,073
-29% -$8.96M
ACIU icon
12
AC Immune
ACIU
$241M
$21.1M 2.75%
2,230,027
+212,527
+11% +$2.01M
INFI
13
DELISTED
Infinity Pharmaceuticals, Inc.
INFI
$20.6M 2.69%
17,426,968
+2,194,700
+14% +$3.95M
PVLA
14
Palvella Therapeutics
PVLA
$2.15B
$19.8M 2.59%
93,224
+23,217
+33% +$7.2M
ARQL
15
DELISTED
Arqule Inc
ARQL
$17.3M 2.26%
6,230,418
+402,516
+7% +$1.54M
CNCE
16
DELISTED
Concert Pharmaceuticals, Inc.
CNCE
$14.4M 1.89%
1,150,445
-441,693
-28% -$6.1M
ANAB icon
17
AnaptysBio
ANAB
$1.63B
$14.1M 1.84%
220,265
-30,000
-12% -$2.23M
MTEM
18
DELISTED
Molecular Templates, Inc.
MTEM
$13.6M 1.78%
224,295
+38,453
+21% +$2.68M
CALA
19
DELISTED
Calithera Biosciences, Inc
CALA
$13.2M 1.73%
164,914
+37,714
+30% +$3.72M
DRNA
20
DELISTED
Dicerna Pharmaceuticals, Inc.
DRNA
$13M 1.7%
1,215,727
+63,654
+6% +$837K
GLMD icon
21
Galmed Pharmaceuticals
GLMD
$4.95M
$12.8M 1.68%
10,436
+650
+7% +$1.14M
VSTM icon
22
Verastem
VSTM
$536M
$11.8M 1.54%
292,833
+127,250
+77% +$7.77M
BLRX
23
BioLineRX
BLRX
$11.7M
$11.4M 1.49%
43,326
– –
XENE icon
24
Xenon Pharmaceuticals
XENE
$6.2B
$11.3M 1.48%
1,788,774
+623,221
+53% +$5.54M
PTGX icon
25
Protagonist Therapeutics
PTGX
$8.92B
$11M 1.44%
1,639,458
-978,509
-37% -$7.76M
1
2 3

Similar funds

GKWIM
Gerber Kawasaki Wealth & Investment Management Santa Monica, California $3.14B AUM 22.62% 1-Year Est. Return
BP
BNP Paribas Paris, France $3.15B AUM 22.54% 1-Year Est. Return
LFG
Larson Financial Group St Louis, Missouri $3.13B AUM 22.88% 1-Year Est. Return
DIG
DeepCurrents Investment Group New York $3.12B AUM 12.93% 1-Year Est. Return
CCI
Cevian Capital II St. Helier, Jersey $3.12B AUM 25.62% 1-Year Est. Return
EA
Emerald Advisers Leola, Pennsylvania $3.16B AUM 109.58% 1-Year Est. Return
FTUS
Flow Traders U.S. New York $3.16B AUM 19.52% 1-Year Est. Return
BFA
Bragg Financial Advisors Charlotte, North Carolina $3.16B AUM 26% 1-Year Est. Return

BVF Inc's Q4 2018 Portfolio in Review

As of Q4 2018, BVF Inc held 58 positions worth $765M, down 33% from $1.14B the previous quarter. Its ten largest holdings account for 53% of the portfolio.

BVF Inc withdrew a net $25.7M in Q4 2018, closing 3 positions and reducing 25 holdings. Its most notable exit was TESARO, Inc., an estimated $5.46M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 83% of assets, down from 85% a quarter earlier.

Against the trend, BVF Inc opened a new position in Eiger BioPharmaceuticals, Inc. worth $6.86M.

  • BVF Inc's largest Q4 2018 buy was Eiger BioPharmaceuticals, Inc.: 22,500 shares worth $6.86M.
  • BVF Inc added most to Arcus Biosciences in Q4 2018, an estimated $15.8M increase.
  • BVF Inc's biggest Q4 2018 reduction was Ionis Pharmaceuticals, cutting an estimated $26M.
  • BVF Inc fully exited TESARO, Inc. in Q4 2018, selling an estimated $5.46M.
  • BVF Inc's ten largest holdings make up 53% of its $765M portfolio in Q4 2018.
  • BVF Inc opened 1 new position and closed 3 in Q4 2018.
  • BVF Inc's portfolio value fell 33% quarter-over-quarter to $765M.

Based on BVF Inc's 13F filing for Q4 2018, filed 14 Feb 2019.